이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Treatment Response in Immune-mediated Myositis Associated Rapidly-progressing Interstitial Lung Disease

2026년 8월 14일 업데이트: Singapore General Hospital

Assessment of Treatment Response in Immune-mediated Myositis Associated Rapidly-progressing Interstitial Lung Disease

Idiopathic inflammatory myopathies (IIM) are a group of autoimmune conditions characterized by inflammation of muscles with possible extra-muscular manifestations which can include skin and interstitial lung disease (ILD). IIM-associated ILD carries poor prognosis. Particular subtypes of IIM such as anti-melanoma differentiation-associated protein 5 positive (anti-MDA5+) dermatomyositis with ILD are most commonly associated with rapidly progressive-interstitial lung disease (RP-ILD). RP-ILD is defined as worsening dyspnoea on exertion, hypoxaemia, and presence of newly emerging or expanding ground glass opacities on radiographic or computed topography of chest imaging excluding drug or infectious cause. Particularly, patients with anti-MDA5+ dermatomyositis often have RP-ILD with high mortality of over 60% in the first six months of diagnosis. The mainstay of treatment is immunosuppression though there has been no highly efficacious therapy proven to date. Therefore, the overall goal is to improve patient outcomes in IIM-associated RP-ILD including those with anti-MDA5+ dermatomyositis through the development of better treatment regimens. The objective of this research study is to evaluate the efficacy and safety of a combined immunosuppressive regime in patients with IIM-associated RP-ILD. The investigators hypothesize that the simultaneous inhibition of particular targets in the innate and adaptive immune system will improve efficacy and patient survival. The approach involves a combination of four immunosuppressive medications targeting different pathways implicated in IIM associated ILD. If successful, this study could contribute significantly to improving clinical outcomes for patients with IIM-associated RP-ILD.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

The primary feature of idiopathic inflammatory myopathies (IIM) is inflammation of muscles, yet extra-muscular manifestations are common such as interstitial lung disease (ILD). Based on both muscular and extra-muscular features, patients can fall into different types of IIMs, including broad subtypes of dermatomyositis (DM), polymyositis (PM), inclusion-body myositis (IBM) and immune-mediating necrotizing myopathies (IMNM). Particular subtypes such as dermatomyositis patients positive for anti-melanoma differentiation-associated protein 5 (anti-MDA5) are most commonly associated with rapidly progressive lung involvement and high mortality, with survival at 1 year being less than 60% despite current available treatment. Treatment for IIM patients involves immunosuppression, though there is no consensus or treatment guidelines available for different subtypes, particularly for myositis-associated RP-ILD. Despite several trials having shown increased efficacy with more aggressive immunosuppressive regimes, mortality still remains high. There is thus an unmet need with regards to treatment of patients with IIM, particularly for myositis-associated RP-ILD.

There is an urgent need to improve outcomes in myositis-associated RP-ILD. Till date, there are no randomised controlled trials that investigate therapy of myositis-associated RP-ILD likely due to the low incidence of the disease. Current best level of evidence for therapies come from single-arm prospective cohort studies with comparison with historical controls. Recent studies using combination therapy to target different aspects of these pathological processes have demonstrated increased efficacy compared to single target alone. This shows that appropriate selection of targets with subsequent combination blockade will be beneficial in treatment of patients with myositis associated RP-ILD. Hence, the investigators propose the utilization of rituximab to block the B-cell involvement, tacrolimus to target T-cells, tofacitinib to block interferon signaling with steroids due to their effects on both the innate and adaptive system in the treatment of myositis-associated RP-ILD. Such combination therapy allows precise targeting of pathways responsible for pathophysiology of the disease, without high individual dosages and hence reducing potential side effects. Till date there are no prospective studies that look into current combination of steroids, tacrolimus, tofacitinib and rituximab in the patients with myositis-associated RP-ILD. However, a drawback for increased immunosuppression is infection, particularly with cytomegalovirus (CMV). The investigators will employ a prophylactic treatment strategy to mitigate the risk of increased infection following higher intensity immunosuppression.

The primary end point will be survival rate at 6 months from initiation of treatment.

Secondary end points include improvement of clinical status, biochemical markers, radiological appearance and parameters on lung function test. Secondary end points also include adverse events rate including side effects from treatment and infection rates.

연구 유형

관찰

등록 (추정된)

80

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

샘플링 방법

비확률 샘플

연구 인구

Patients currently undergoing treatment with combined immunosuppressive treatment for myositis-associated rapidly progressive interstitial lung disease

설명

Inclusion Criteria:

  1. Age of 21 years or above;
  2. Diagnosis of myositis associated rapidly progressive interstitial lung disease

Exclusion Criteria:

  1. Age of less than 21 year old;

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

코호트 및 개입

그룹/코호트
개입 / 치료
Treatment group
Patients with immune-mediated myositis-associated rapidly progressive interstitial lung disease undergoing treatment with combined immunosuppressive treatment
Combination treatment regimen lasting 6 months with A) Steroids: Starting with Intravenous methylprednisolone (500mg once daily for three days) followed by tapering dose of prednisolone B) Rituximab (1000mg given at the start of treatment and 1000mg 2 weeks after the first dose) C) Tacrolimus D) Tofacitinib
다른 이름들:
  • 리툭시맙
  • 프레드니솔론
  • 타크로리무스
  • 토파시티닙

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
All-cause mortality at 6 months from treatment initiation
기간: 6 months
Proportion of total participants who demise from all cause till 6 months from treatment initiation (percentage of all participants)
6 months

2차 결과 측정

결과 측정
측정값 설명
기간
Change in clinical status through Modified Medical Research Council Dyspnea Scale
기간: 6 months
The Modified Medical Research Council (mMRC) Dyspnea Scale will be used to rate participants' functional status at start of treatment and at 6 months post treatment (0 to 4).
6 months
Change in clinical status through requirement of supplemental oxygen at 6 months
기간: 6 months
Proportion of participants who require oxygen supplementation at the start of treatment and 6 months post treatment (percentage of all participants).
6 months
Safety of treatment regimen in participants
기간: 6 months
Number of adverse infection events experienced by participants
6 months
Safety of treatment regimen in participants
기간: 6 months
Number of adverse haematological events leading to change of medication as per managing physician
6 months
Safety of treatment regimen in participants
기간: 6 months
Number of adverse biochemical events leading to change of medication as per managing physician
6 months
Change in biochemical markers of disease activity
기간: 1 year
Levels of C-reactive protein (mg/L) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year
1 year
Change in biochemical markers of disease activity
기간: 1 year
Levels of Erythrocyte sedimentation rate (mm/h) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year.
1 year
Change in biochemical markers of disease activity
기간: 1 year
Levels of Ferritin (ug/L) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year.
1 year
Change in biochemical markers of disease activity
기간: 1 year
Levels of Lactate dehydrogenase (U/L) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year.
1 year
Change in biochemical markers of disease activity
기간: 1 year
Levels of Creatine kinase (U/L) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year.
1 year
Change in biochemical markers of disease activity
기간: 1 year
Levels of Aldolase (U/L) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year.
1 year

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 12월 26일

기본 완료 (추정된)

2029년 7월 1일

연구 완료 (추정된)

2029년 7월 1일

연구 등록 날짜

최초 제출

2026년 4월 23일

QC 기준을 충족하는 최초 제출

2026년 8월 14일

처음 게시됨 (실제)

2026년 8월 20일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 8월 20일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 8월 14일

마지막으로 확인됨

2025년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 2024/2307

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .